CytomX Therapeutics, Inc.

Wednesday, CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity.  As of April 16, 2024, data cutoff, the Phase 1 study enrolled 35 heavily pretreated patients with advanced metastatic solid tumor types. CX-904 demonstrated a favorable safety profile, supporting administration and monitoring enrolled patients in an outpatient setting. Eight patients had measurable tumor reduction at data cutoff, including 2 of 6 efficacy-evaluable patients (33%) with pancreatic cancer with confirmed partial responses. All six efficacy-evaluable patients with pancreatic cancer achieved disease control (objective response or stable disease).  One patient (6 mg target dose) achieved an 83% tumor reduction for the two patients with a confirmed partial response. The second patient (5 mg target dose) with a confirmed response achieved a 51% ...Full story available on Benzinga.com

Related tickers: CTMX.

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -

Related tickers: CTMX.